Download our whitepaper,

Migraine Clinical Trials: Advancing
Treatment Strategies

What's Inside:

  • Pathophysiology and classification of migraine disorders.
  • Endpoints for acute and preventive migraine trials.
  • Patient-reported outcomes and pain assessment tools.
  • CGRP-targeted therapies and novel drug mechanisms.
  • Trial design challenges in episodic vs. chronic migraine.
  • Improving patient retention and data consistency.

Access your complimentary whitepaper today:






    Migraine

    Migraine is a prevalent neurological disorder characterized by recurrent, debilitating headaches that can significantly impact a person’s quality of life.

    The evolution of migraine management has been marked by a growing range of FDA-approved drugs, reflecting significant progress in therapeutic innovation and understanding of the condition.

    To enhance patient outcomes in migraine clinical trials, it is important to focus not only on the physiological aspects of migraine relief but also on improvements in quality of life. This includes considering endpoints that are meaningful to daily living and long-term health.

    At iNGENū, our team of researchers and clinicians is dedicated to advancing migraine research. Through innovative trial designs and a patient-centered approach, we strive to accelerate the development of new treatments that could offer improved options and outcomes for individuals affected by migraine.

    1B

    people worldwide are affected by migraines — the 3rd most prevalent illness globally

    18%

    of women experience migraines, making them more common among females

    90%

    of migraine sufferers have a family history, indicating a strong genetic predisposition

    Our clinical team has over

    120

    years of combined clinical trial experience